Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma

Summary

This study plans to use 1.0×108PFU/day per cycle, intratumoral injection administration for 3 consecutive days, and 28 days as a cycle. Tumor imaging evaluation was performed every 8±1 weeks from the first dose of C1D1 until an event that met the criteria for treatment discontinuation occurred.

Timeline

Start

2023-07-18

Primary completion

2025-07-17

Completion

2026-01-17

Drugs

Indications